Dapagliflozin transforms into heart failure drug
DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug Proof that dapagliflozin significantly helped heart failure patients without diabetes recategorizes the drug as a major agent for treating heart failure. New hypertension cases halved with community-wide salt substitution Social marketing principles achieved near-universal salt replacement, village by village, in rural Peru. Ticagrelor: Modest benefit, bigger bleed risk in diabetes plus stable CAD Patients with prior PCI fared a bit better and may be a target population for long-term DAPT therapy. In PAD, dropping statins ups death risk 43% Statin adherence saves lives in peripheral arterial disease.